Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of nivolumab plus mFOLFIRINOX in metastatic pancreatic cancer (TASUKI-83)
jRCT2080224169Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2080224169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224169.